The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: An update

Hormones

Volumn 14, Issue 3, 2015, Pages 370-375

  Christou, Georgios A ^a   Kiortsis, Dimitrios N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Bupropion; Naltrexone; Obesity

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; NALTREXONE; NARCOTIC ANTAGONIST;

BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; COMORBIDITY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HUMAN; INSOMNIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SUICIDAL IDEATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

BUPROPION; DOPAMINE UPTAKE INHIBITORS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84938497651     PISSN: 11093099     EISSN: 25208721     Source Type: Journal    
DOI: 10.14310/horm.2002.1600     Document Type: Review

References (20)

1. Jensen MD, Ryan DH, Apovian CM, et al, 2014 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129: 25 Suppl 2: 102-138.
2. Kiortsis DN, Filippatos TD, Elisaf MS, 2005 The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 31: 15-22.
3. Christopoulou FD, Kiortsis DN, 2011 An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36: 10-18.
4. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS, 2005 A review of the metabolic effects of sibutramine. Curr Med Res Opin 21: 457-468.
5. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC, 2013 Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 14: 383-392.
6. Kiortsis DN, 2013 A review of the metabolic effects of controlled-release Phentermine/Topiramate. Hormones (Athens) 12: 507-516.
7. Iepsen EW, Torekov SS, Holst JJ, 2014 Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother 15: 2487-2500.
8. Greenway FL, Fujioka K, Plodkowski RA, et al, 2010 Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376: 595-605.
9. Pucci A, Finer N, 2015 New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects. Can J Cardiol 31: 142-152.
10. Gadde KM, Xiong GL, 2007 Bupropion for weight reduction. Expert Rev Neurother 7: 17-24.
11. Greenway FL, Whitehouse MJ, Guttadauria M, et al, 2009 Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17: 30-39.
12. Greenway FL, Dunayevich E, Tollefson G, et al, 2009 Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94: 4898-4906.
13. Smith SR, Fujioka K, Gupta AK, et al, 2013 Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 15: 863-866.
14. Wadden TA, Foreyt JP, Foster GD, et al, 2011 Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19: 110-120.
15. Apovian CM, Aronne L, Rubino D, et al, 2013 A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21: 935-943.
16. Hollander P, Gupta AK, Plodkowski R, et al, 2013 Effects of naltrexone sustained-release/bupropion sustained- release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36: 4022-4029.
17. Wilcox CS, Oskooilar N, Erickson JS, et al, 2010 An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 35: 229-234.
18. Després JP, 2012 Body fat distribution and risk of cardiovascular disease: an update. Circulation 126: 1301-1313.
19. Ross R, Janiszewski PM, 2008 Is weight loss the optimal target for obesity-related cardiovascular disease risk reduction? Can J Cardiol 24: Suppl D: 25D-31D.
20. Thase ME, Haight BR, Johnson MC, et al, 2008 A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 28: 302-307.